Forus, an AI network built to connect doctors, pharmacies, payers and biopharmaceutical companies in order to speed the delivery of new medicines to patients, has raised $150 million in Series C funding at a $3 billion valuation, the company confirmed on September 8, 2026. The round was led by Bain Capital Ventures, with participation from Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures and SV Angel. Founded in 2023 by Sahir Jaggi, Forus has now raised more than $300 million in total reported equity funding.
The company's platform addresses a persistent inefficiency in the US healthcare system: the fragmented, often manual coordination required to get newly approved or specialised medications from prescription to patient, particularly for complex therapies that require prior authorisation, specialty pharmacy routing or manufacturer-sponsored patient support programmes. By connecting the key stakeholders in that chain — prescribing physicians, dispensing pharmacies, insurance payers and the pharmaceutical companies manufacturing the drugs — through a shared AI-driven coordination layer, Forus aims to reduce the delays and administrative friction that frequently prevent patients from receiving prescribed treatments promptly.
The rapid ascent to a $3 billion valuation, achieved roughly two years after the company's founding, reflects the intensity of investor interest in AI applications addressing healthcare's administrative and coordination bottlenecks — a category that has attracted substantial venture capital as investors distinguish between AI applied to clinical diagnosis or drug discovery and AI applied to the equally consequential but less publicly visible problem of healthcare logistics and administrative coordination.
Forus's investor syndicate, spanning some of the most active healthcare and technology-focused venture firms in the United States, suggests broad institutional conviction in the company's approach. The involvement of both generalist growth investors like Thrive Capital and General Catalyst alongside specialised healthcare investors indicates that Forus's platform is being evaluated not purely as a healthcare-technology bet but as a broader infrastructure play with potential relevance across multiple points in the pharmaceutical supply and prescribing chain.
The prescription-fulfilment coordination problem Forus is addressing has become increasingly acute as the pharmaceutical industry has shifted toward more complex, higher-cost specialty medications requiring more intensive coordination between prescribers, payers and manufacturers than traditional generic drug dispensing. As specialty and precision medicines continue to represent a growing share of new drug approvals, the administrative infrastructure required to deliver those treatments efficiently has struggled to keep pace — creating the exact structural gap Forus's platform is designed to close.
For the broader healthtech investment landscape, Forus's raise adds to a growing body of evidence that AI-driven coordination and administrative-efficiency platforms are attracting some of the largest and fastest-growing valuations within digital health, even as more consumer-facing healthtech categories have faced a more cautious funding environment. Whether Forus can translate its substantial capital base and investor backing into durable, defensible market position will depend heavily on the depth of integration it achieves across its physician, pharmacy, payer and manufacturer partner network over the coming years.
